Mid-term clinical outcomes following SAPIEN 3 20-mm transcatheter aortic valve implantation in patients with symptomatic severe aortic valve stenosis.

Mid-term clinical outcomes following SAPIEN 3 20-mm transcatheter aortic valve implantation in patients with symptomatic severe aortic valve stenosis. - Mid-term clinical outcomes following SAPIEN 3 20-mm transcatheter aortic valve implantation in patients with symptomatic severe aortic valve stenosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057921

Enrollment

400

Registered

2025-05-23

Start date

2025-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 70 to 100 who underwent transcatheter aortic valve implantation.

Exclusion criteria

Exclusion criteria: Patients who received self-expanding bioprosthetic valves or underwent transcatheter aortic valve implantation for structural valve degeneration were excluded.

Design outcomes

Primary

Measure	Time frame
We investigated all-cause mortality in patients who underwent transcatheter aortic valve implantation (TAVI) of SAPIEN3 20mm transcatheter heart valve at our institution.	—

Secondary

Measure	Time frame
We investigated cardiovascular mortality, heart failure hospitalization, and echocardiographic data in patients who underwent transcatheter aortic valve implantation (TAVI) of SAPIEN3 20mm transcatheter heart valve at our institution.	—

Countries

Japan

Contacts

Public ContactShunichi Imamura

National Hospital Organization Kagoshima Medical Center Department of Cardiology

www.haruichi.vs.syunichi@gmail.com+81-99-223-1151

Outcome results